ArticleMolecular diversity2026
Prediction of drug-induced nephrotoxicity based on deep learning algorithm and molecular fingerprints.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of machine learning-based multi-task quantitative structure-activity relationship models for predicting toxicities in six human organ systems.Computational toxicology (Amsterdam, Netherlands) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Drug-induced nephrotoxicity (DIN) is an infrequent adverse reaction to medications and represents a complex clinical outcome influenced by multiple factors. Predicting DIN using preclinical animal models remains challenging, and in silico approaches have emerged as promising alternatives for DIN risk assessment. A high-quality dataset consisting of 1,018 compounds was constructed in this study. Compounds in this dataset were systematically collected from five authoritative sources: the SIDER, FDA, ChEMBL, DrugBank, and literature on "drug-induced nephrotoxicity" published in the past decade (screened via keyword search on PubMed). Clear criteria were followed for compound screening and label annotation: using "kidney," "nephrotoxicity," "kidney injury," and "kidney disease" as core search terms, compounds retrieved that were clearly associated with kidney injury or could induce kidney disease were classified into the positive set (DIN = 1); compounds with no records of renal adverse reactions, or those explicitly having renal protective effects or used for treating renal diseases, were classified into the negative set (DIN = 0). Ultimately, a dataset of 1018 compounds with clear labels and reliable sources was integrated. The 42 classification models, which depended on six different molecular fingerprints, were built via deep neural network (DNN) and six machine learning algorithms. A comparative study demonstrated that models utilizing DNN consistently surpassed traditional machine learning approaches across six molecular fingerprint types. Notably, the ECFP_6 fingerprint exhibited the highest performance, achieving an area under the receiver operating characteristic curve (AUC) of 75.9%, an accuracy (ACC) of 71.4%, and an F1-score of 76.0%. Furthermore, the SHapley Additive exPlanations (SHAP) algorithm was applied to interpret the predictions of the high-performing models, identifying key structural fragments associated with DIN. The ten most influential substructures, identified based on their impact on model predictions, were chosen as early warning markers for future DIN screening research. Overall, these results suggest that DNN models utilizing molecular fingerprints can function as dependable and efficient tools for assessing nephrotoxicity risk in potential drug candidates during the initial phases of drug development.
Indexed as
Identifiers
41077577What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.